Review

amiodarone hydrochloride (LKT Laboratories)

Name: amiodarone hydrochloride
Brand: LKT Laboratories
Rating: 93 (8 reviews)

LKT Laboratories is a verified supplier

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

LKT Laboratories amiodarone hydrochloride
$Fig. 1. Decreased serum concentrations of lipids and VLDL/LDL-philic drugs were observed in lomitapide-treated mice. (A) Diagram showing the repeated co- administration study in mice. The study schedule consisted of a 7-day single administration period and a 4-day co-administration period. (B) Cholesterol, (C) tri glyceride, (D) <t>amiodarone,</t> (E) tetracycline, (F) doxycycline, and (G) labetalol concentrations in the serum and VLDL/LDL fractions were measured at the end of the repeated co-administration study. n = 6 mice per group. Data are presented as individual values with mean ± SEM. *p < 0.05, **p < 0.01, significantly different from the lomitapide-untreated group; N.S., not significant from the lomitapide-untreated group; unpaired Student’s t test.$
Amiodarone Hydrochloride, supplied by LKT Laboratories, used in various techniques. Bioz Stars score: 93/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/amiodarone hydrochloride/product/LKT Laboratories
Average 93 stars, based on 8 article reviews

amiodarone hydrochloride - by Bioz Stars, 2026-02

93/100 stars

Images

1) Product Images from "Preclinical evaluation of new drug-drug interactions of lomitapide: A proposal for novel mechanism of interaction associated with lipid metabolic changes."

Article Title: Preclinical evaluation of new drug-drug interactions of lomitapide: A proposal for novel mechanism of interaction associated with lipid metabolic changes.

Journal: Biochemical pharmacology

doi: 10.1016/j.bcp.2025.116778

$Fig. 1. Decreased serum concentrations of lipids and VLDL/LDL-philic drugs were observed in lomitapide-treated mice. (A) Diagram showing the repeated co- administration study in mice. The study schedule consisted of a 7-day single administration period and a 4-day co-administration period. (B) Cholesterol, (C) tri glyceride, (D) amiodarone, (E) tetracycline, (F) doxycycline, and (G) labetalol concentrations in the serum and VLDL/LDL fractions were measured at the end of the repeated co-administration study. n = 6 mice per group. Data are presented as individual values with mean ± SEM. *p < 0.05, **p < 0.01, significantly different from the lomitapide-untreated group; N.S., not significant from the lomitapide-untreated group; unpaired Student’s t test.$
Figure Legend Snippet: Fig. 1. Decreased serum concentrations of lipids and VLDL/LDL-philic drugs were observed in lomitapide-treated mice. (A) Diagram showing the repeated co- administration study in mice. The study schedule consisted of a 7-day single administration period and a 4-day co-administration period. (B) Cholesterol, (C) tri glyceride, (D) amiodarone, (E) tetracycline, (F) doxycycline, and (G) labetalol concentrations in the serum and VLDL/LDL fractions were measured at the end of the repeated co-administration study. n = 6 mice per group. Data are presented as individual values with mean ± SEM. *p < 0.05, **p < 0.01, significantly different from the lomitapide-untreated group; N.S., not significant from the lomitapide-untreated group; unpaired Student’s t test.

Techniques Used:

Fig. 2. Accumulation of lipids and VLDL/LDL-philic drugs was observed in enterocytes of lomitapide-treated mice. The amount of (A) cholesterol (n = 6 mice per group), (B) triglycerides (n = 6 mice per group), (C) amiodarone (n = 6 mice per group), (D) tetracycline (n = 5 mice per group; one point was excluded as an outlier), and (E) doxycycline (n = 6 mice per group) in enter ocytes was measured at the end of the repeated co-administration study. Data are presented as individual values with mean ± SEM. *p < 0.05, **p < 0.01, significantly different from the lomitapide-untreated group; N.S., not significant from the lomitapide-untreated group; unpaired Student’s t test.

Figure Legend Snippet: Fig. 2. Accumulation of lipids and VLDL/LDL-philic drugs was observed in enterocytes of lomitapide-treated mice. The amount of (A) cholesterol (n = 6 mice per group), (B) triglycerides (n = 6 mice per group), (C) amiodarone (n = 6 mice per group), (D) tetracycline (n = 5 mice per group; one point was excluded as an outlier), and (E) doxycycline (n = 6 mice per group) in enter ocytes was measured at the end of the repeated co-administration study. Data are presented as individual values with mean ± SEM. *p < 0.05, **p < 0.01, significantly different from the lomitapide-untreated group; N.S., not significant from the lomitapide-untreated group; unpaired Student’s t test.

Techniques Used:

Fig. 3. Accumulation of lipids, but not of VLDL/LDL-philic drugs, was observed in the liver of lomitapide-treated mice. The amount of (A) cholesterol, (B) tri glycerides, (C) amiodarone, (D) tetracycline, and (E) doxycycline in the liver was measured at the end of the repeated co-administration study. n = 6 mice per group. Data are presented as individual values with mean ± SEM. *p < 0.05, **p < 0.01, significantly different from the lomitapide-untreated group; N.S., not significant from the lomitapide-untreated group; unpaired Student’s t test.

Figure Legend Snippet: Fig. 3. Accumulation of lipids, but not of VLDL/LDL-philic drugs, was observed in the liver of lomitapide-treated mice. The amount of (A) cholesterol, (B) tri glycerides, (C) amiodarone, (D) tetracycline, and (E) doxycycline in the liver was measured at the end of the repeated co-administration study. n = 6 mice per group. Data are presented as individual values with mean ± SEM. *p < 0.05, **p < 0.01, significantly different from the lomitapide-untreated group; N.S., not significant from the lomitapide-untreated group; unpaired Student’s t test.

Techniques Used:

$Fig. 4. Inhibition of amiodarone absorption was observed in lomitapide-pretreated mice. (A) Diagram showing the acute absorption study in mice. The study schedule consisted of a 7-day preadministration period followed by the oral administration of amiodarone with olive oil. (B) Cholesterol and (C) triglyceride concentrations in the serum and VLDL/LDL fractions were measured at the end of the 7-day preadministration period. (D) Triglyceride and (E) amiodarone con centrations in the serum and (F) amiodarone concentrations in VLDL/LDL fractions were measured before and 1 and 2 h after the oral administration of amiodarone with olive oil. (G) Amiodarone levels in enterocytes 2 h after oral administration. Black line: lomitapide-untreated group; blue line: lomitapide-pretreated group. n = 6 mice per group. Data are presented as individual values with mean ± SEM. *p < 0.05, **p < 0.01, significantly different from the lomitapide-untreated group; N.S., not significant from the lomitapide-untreated group; unpaired Student’s t test.$
Figure Legend Snippet: Fig. 4. Inhibition of amiodarone absorption was observed in lomitapide-pretreated mice. (A) Diagram showing the acute absorption study in mice. The study schedule consisted of a 7-day preadministration period followed by the oral administration of amiodarone with olive oil. (B) Cholesterol and (C) triglyceride concentrations in the serum and VLDL/LDL fractions were measured at the end of the 7-day preadministration period. (D) Triglyceride and (E) amiodarone con centrations in the serum and (F) amiodarone concentrations in VLDL/LDL fractions were measured before and 1 and 2 h after the oral administration of amiodarone with olive oil. (G) Amiodarone levels in enterocytes 2 h after oral administration. Black line: lomitapide-untreated group; blue line: lomitapide-pretreated group. n = 6 mice per group. Data are presented as individual values with mean ± SEM. *p < 0.05, **p < 0.01, significantly different from the lomitapide-untreated group; N.S., not significant from the lomitapide-untreated group; unpaired Student’s t test.

Techniques Used: Inhibition

Image Search Results

Amiodarone decreases proliferation in bladder cancer cell lines. Real-time proliferation assays in UMUC3, HT1197, BFTC905, and RT112 were conducted using the Incucyte S3 system. The cells were treated with increasing concentrations of amiodarone (0–50 μmol/L), and the confluence was measured every 4 hours over 96 hours. A, Cell confluence over time. B, Cell confluence after 96 hours of treatment. Data represent mean ± SEM from at least three independent experiments (one-way ANOVA with Dunnett’s multiple comparisons test; *, P < 0.05; ***, P < 0.001; ****, P < 0.0001). C, Concentration–response curves and IC 50 values for amiodarone after 96 hours of treatment.

Journal: Cancer Research Communications

Article Title: Repurposing Amiodarone for Bladder Cancer Treatment

doi: 10.1158/2767-9764.CRC-24-0433

Figure Lengend Snippet: Amiodarone decreases proliferation in bladder cancer cell lines. Real-time proliferation assays in UMUC3, HT1197, BFTC905, and RT112 were conducted using the Incucyte S3 system. The cells were treated with increasing concentrations of amiodarone (0–50 μmol/L), and the confluence was measured every 4 hours over 96 hours. A, Cell confluence over time. B, Cell confluence after 96 hours of treatment. Data represent mean ± SEM from at least three independent experiments (one-way ANOVA with Dunnett’s multiple comparisons test; *, P < 0.05; ***, P < 0.001; ****, P < 0.0001). C, Concentration–response curves and IC 50 values for amiodarone after 96 hours of treatment.

Article Snippet: Amiodarone hydrochloride was purchased from STADAPHARM GmbH and dissolved in sterile water.

Techniques: Concentration Assay

Amiodarone decreases colony formation capacity in bladder cancer cell lines. Cells seeded in six-well plates were treated with increasing concentrations of amiodarone (0–5 μmol/L). After incubation for 7 to 10 days, the cells were stained with crystal violet, and the plates were scanned. A, Representative images of the colonies. B, Quantification of the colony number. Data are presented as the number of colonies related to the control and represent mean ± SEM from three independent experiments (one-way ANOVA with Dunnett’s multiple comparisons test; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).

Journal: Cancer Research Communications

Article Title: Repurposing Amiodarone for Bladder Cancer Treatment

doi: 10.1158/2767-9764.CRC-24-0433

Figure Lengend Snippet: Amiodarone decreases colony formation capacity in bladder cancer cell lines. Cells seeded in six-well plates were treated with increasing concentrations of amiodarone (0–5 μmol/L). After incubation for 7 to 10 days, the cells were stained with crystal violet, and the plates were scanned. A, Representative images of the colonies. B, Quantification of the colony number. Data are presented as the number of colonies related to the control and represent mean ± SEM from three independent experiments (one-way ANOVA with Dunnett’s multiple comparisons test; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).

Article Snippet: Amiodarone hydrochloride was purchased from STADAPHARM GmbH and dissolved in sterile water.

Techniques: Incubation, Staining, Control

Amiodarone induces apoptosis in bladder cancer cell lines. Cells were treated for 48 or 72 hours with amiodarone (0, 25, and 50 μmol/L for UMUC3; 0, 12.5, and 25 μmol/L for HT1197, BFTC905, and RT112). A, Apoptosis was evaluated using the Caspase-Glo 3/7 Assay and viability using the CellTiter cell proliferation assay. Apoptosis results were normalized to viability. Data are presented as apoptosis related to the control and represent mean ± SEM from at least three independent experiments (one-way ANOVA with Dunnett’s multiple comparisons test; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001). B, Western blot analysis of cPARP expression after 48 hours of treatment with 0, 12.5, and 25 μmol/L amiodarone. GAPDH was used as a loading control. Blots are representative of three independent experiments. Quantification of cPARP expression (normalized by GAPDH) is indicated under each corresponding band. Values are presented as expression related to the control.

Journal: Cancer Research Communications

Article Title: Repurposing Amiodarone for Bladder Cancer Treatment

doi: 10.1158/2767-9764.CRC-24-0433

Figure Lengend Snippet: Amiodarone induces apoptosis in bladder cancer cell lines. Cells were treated for 48 or 72 hours with amiodarone (0, 25, and 50 μmol/L for UMUC3; 0, 12.5, and 25 μmol/L for HT1197, BFTC905, and RT112). A, Apoptosis was evaluated using the Caspase-Glo 3/7 Assay and viability using the CellTiter cell proliferation assay. Apoptosis results were normalized to viability. Data are presented as apoptosis related to the control and represent mean ± SEM from at least three independent experiments (one-way ANOVA with Dunnett’s multiple comparisons test; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001). B, Western blot analysis of cPARP expression after 48 hours of treatment with 0, 12.5, and 25 μmol/L amiodarone. GAPDH was used as a loading control. Blots are representative of three independent experiments. Quantification of cPARP expression (normalized by GAPDH) is indicated under each corresponding band. Values are presented as expression related to the control.

Article Snippet: Amiodarone hydrochloride was purchased from STADAPHARM GmbH and dissolved in sterile water.

Techniques: Caspase-Glo Assay, Proliferation Assay, Control, Western Blot, Expressing

Amiodarone reduces bladder cancer tumor growth in vivo . Tumor growth in BFTC905-bearing NOD/SCID mice treated with 75 mg/kg of amiodarone. A, Tumor volume over time in control ( n = 6) and amiodarone-treated ( n = 6) tumor-bearing animals during a 3-week cycle treatment. Data represent mean ± SEM (Student t test; **, P < 0.01). B, Body weight of control and amiodarone-treated animals after 27 days of the experiment. Data represent mean ± SEM (Student t test; ****, P < 0.0001). C, Histologic analysis of liver, kidney, and heart sections derived from control and amiodarone-treated animals. Representative hematoxylin and eosin images are shown. D, Heatmap of the top 20 upregulated and top 20 downregulated genes identified by RNA-seq expression analysis of xenograft tumor samples. E, Top 10 significantly deregulated pathways identified by the RNA-seq analysis. F, Gene set enrichment analysis barcode plots for the top five significantly deregulated pathways. G, Heatmap showing the expression of the apoptosis-inducing ligand TNFSF10 and mitochondrially encoded genes of the electron transport chain. H, Dot plot representing the apoptosis gene set activity score derived from RNA-seq gene expression data. FC, fold change.

Journal: Cancer Research Communications

Article Title: Repurposing Amiodarone for Bladder Cancer Treatment

doi: 10.1158/2767-9764.CRC-24-0433

Figure Lengend Snippet: Amiodarone reduces bladder cancer tumor growth in vivo . Tumor growth in BFTC905-bearing NOD/SCID mice treated with 75 mg/kg of amiodarone. A, Tumor volume over time in control ( n = 6) and amiodarone-treated ( n = 6) tumor-bearing animals during a 3-week cycle treatment. Data represent mean ± SEM (Student t test; **, P < 0.01). B, Body weight of control and amiodarone-treated animals after 27 days of the experiment. Data represent mean ± SEM (Student t test; ****, P < 0.0001). C, Histologic analysis of liver, kidney, and heart sections derived from control and amiodarone-treated animals. Representative hematoxylin and eosin images are shown. D, Heatmap of the top 20 upregulated and top 20 downregulated genes identified by RNA-seq expression analysis of xenograft tumor samples. E, Top 10 significantly deregulated pathways identified by the RNA-seq analysis. F, Gene set enrichment analysis barcode plots for the top five significantly deregulated pathways. G, Heatmap showing the expression of the apoptosis-inducing ligand TNFSF10 and mitochondrially encoded genes of the electron transport chain. H, Dot plot representing the apoptosis gene set activity score derived from RNA-seq gene expression data. FC, fold change.

Article Snippet: Amiodarone hydrochloride was purchased from STADAPHARM GmbH and dissolved in sterile water.

Techniques: In Vivo, Control, Derivative Assay, RNA Sequencing, Expressing, Activity Assay, Gene Expression

Amiodarone inhibits mTOR and MAPK pathways. Cells were treated for 24 hours with increasing concentrations of amiodarone (0, 12.5, and 25 μmol/L), and the expression of the proteins AKT, mTOR, S6, and p44/42 MAPK, both phosphorylated (p-) and total, was analyzed by Western blot. GAPDH was used as a loading control. Blots are representative of three independent experiments. Quantification of the protein expression (normalized by GAPDH) is indicated under each corresponding band. Values are presented as expression related to the control. n.d., not determined.

Journal: Cancer Research Communications

Article Title: Repurposing Amiodarone for Bladder Cancer Treatment

doi: 10.1158/2767-9764.CRC-24-0433

Figure Lengend Snippet: Amiodarone inhibits mTOR and MAPK pathways. Cells were treated for 24 hours with increasing concentrations of amiodarone (0, 12.5, and 25 μmol/L), and the expression of the proteins AKT, mTOR, S6, and p44/42 MAPK, both phosphorylated (p-) and total, was analyzed by Western blot. GAPDH was used as a loading control. Blots are representative of three independent experiments. Quantification of the protein expression (normalized by GAPDH) is indicated under each corresponding band. Values are presented as expression related to the control. n.d., not determined.

Article Snippet: Amiodarone hydrochloride was purchased from STADAPHARM GmbH and dissolved in sterile water.

Techniques: Expressing, Western Blot, Control

Chemical structures of ravuconazole (A) and amiodarone (B).

Journal: ACS Omega

Article Title: Amiodarone and Ravuconazole Combination Potentiates Chemotherapy against Drug-Resistant Trypanosoma cruzi Strains

doi: 10.1021/acsomega.5c00996

Figure Lengend Snippet: Chemical structures of ravuconazole (A) and amiodarone (B).

Article Snippet: Amiodarone hydrochloride was purchased from Sanofi Aventis (Paris, France).

Techniques:

Effects of ravuconazole and amiodarone combination on host and parasites. (A) Viability of uninfected H9c2 cells incubated with ravuconazole and amiodarone, individually and in combination, for 48 h. ** p < 0.01; **** p < 0.0001 compared to the same concentration of amiodarone in monotherapy. (B,C) Isobolograms representing the absence of interaction between ravuconazole and amiodarone against intracellular amastigotes of the Y T. cruzi strain at EC 50 (B) and EC 90 (C) levels. The dotted lines indicate the theoretical thresholds for synergism (<0.5) and antagonism (>4).

Journal: ACS Omega

Article Title: Amiodarone and Ravuconazole Combination Potentiates Chemotherapy against Drug-Resistant Trypanosoma cruzi Strains

doi: 10.1021/acsomega.5c00996

Figure Lengend Snippet: Effects of ravuconazole and amiodarone combination on host and parasites. (A) Viability of uninfected H9c2 cells incubated with ravuconazole and amiodarone, individually and in combination, for 48 h. ** p < 0.01; **** p < 0.0001 compared to the same concentration of amiodarone in monotherapy. (B,C) Isobolograms representing the absence of interaction between ravuconazole and amiodarone against intracellular amastigotes of the Y T. cruzi strain at EC 50 (B) and EC 90 (C) levels. The dotted lines indicate the theoretical thresholds for synergism (<0.5) and antagonism (>4).

Article Snippet: Amiodarone hydrochloride was purchased from Sanofi Aventis (Paris, France).

Techniques: Incubation, Concentration Assay

Effects of ravuconazole and amiodarone combination on a benznidazole partially resistant T. cruzi strain. Parasitemia curves and areas under parasitemia curves for BALB/c (A,C) and Swiss (B,D) mice infected with Y T. cruzi strain and treated with benznidazole at 100 mg/kg body weight (Bz); ravuconazole at 0.5 mg/kg (Rav 0.5); ravuconazole at 10 mg/kg (Rav 10); amiodarone at 50 mg/kg (Amio) or a combination of ravuconazole 0.5 mg/kg and amiodarone 50 mg/kg (Rav + Amio). Infected untreated controls (INT) received water. Treatments were administered orally from the 5th to the 9th day after infection. Insets in A and B show parasitemia curves excluding mice treated with amiodarone and untreated controls. Data are presented as mean ± SD. Asterisks indicate significant differences compared to infected untreated mice. * p < 0.05, ** p < 0.01, *** p < 0.001. p -Values for comparisons between combination therapies and monotherapies at equivalent doses are shown in the graphs.

Journal: ACS Omega

Article Title: Amiodarone and Ravuconazole Combination Potentiates Chemotherapy against Drug-Resistant Trypanosoma cruzi Strains

doi: 10.1021/acsomega.5c00996

Figure Lengend Snippet: Effects of ravuconazole and amiodarone combination on a benznidazole partially resistant T. cruzi strain. Parasitemia curves and areas under parasitemia curves for BALB/c (A,C) and Swiss (B,D) mice infected with Y T. cruzi strain and treated with benznidazole at 100 mg/kg body weight (Bz); ravuconazole at 0.5 mg/kg (Rav 0.5); ravuconazole at 10 mg/kg (Rav 10); amiodarone at 50 mg/kg (Amio) or a combination of ravuconazole 0.5 mg/kg and amiodarone 50 mg/kg (Rav + Amio). Infected untreated controls (INT) received water. Treatments were administered orally from the 5th to the 9th day after infection. Insets in A and B show parasitemia curves excluding mice treated with amiodarone and untreated controls. Data are presented as mean ± SD. Asterisks indicate significant differences compared to infected untreated mice. * p < 0.05, ** p < 0.01, *** p < 0.001. p -Values for comparisons between combination therapies and monotherapies at equivalent doses are shown in the graphs.

Article Snippet: Amiodarone hydrochloride was purchased from Sanofi Aventis (Paris, France).

Techniques: Infection

Combination therapy protects mice infected with Y T. cruzi strain from weight loss. Weight gain observed in BALB/c (A) and Swiss (B) mice infected with Y T. cruzi strain and treated with benznidazole at 100 mg/kg body weight (Bz); ravuconazole at 0.5 mg/kg (Rav 0.5); ravuconazole at 10 mg/kg (Rav 10); amiodarone at 50 mg/kg (Amio) or a combination of ravuconazole 0.5 mg/kg and amiodarone 50 mg/kg (Rav + Amio). Infected untreated controls (INT) received water. NICnon infected controls. Treatments were administered orally from the 5th to the 9th day after infection. Weight gain was calculated as the difference between final weight (14 days postinfection) and initial weight (5 days postinfection). Data are presented as mean ± SD and analyzed using the Mann–Whitney test. Asterisks indicate significant differences compared to infected untreated mice. * p < 0.05. p -Values for comparisons between combination therapies and monotherapies at equivalent doses are shown in the graphs.

Journal: ACS Omega

Article Title: Amiodarone and Ravuconazole Combination Potentiates Chemotherapy against Drug-Resistant Trypanosoma cruzi Strains

doi: 10.1021/acsomega.5c00996

Figure Lengend Snippet: Combination therapy protects mice infected with Y T. cruzi strain from weight loss. Weight gain observed in BALB/c (A) and Swiss (B) mice infected with Y T. cruzi strain and treated with benznidazole at 100 mg/kg body weight (Bz); ravuconazole at 0.5 mg/kg (Rav 0.5); ravuconazole at 10 mg/kg (Rav 10); amiodarone at 50 mg/kg (Amio) or a combination of ravuconazole 0.5 mg/kg and amiodarone 50 mg/kg (Rav + Amio). Infected untreated controls (INT) received water. NICnon infected controls. Treatments were administered orally from the 5th to the 9th day after infection. Weight gain was calculated as the difference between final weight (14 days postinfection) and initial weight (5 days postinfection). Data are presented as mean ± SD and analyzed using the Mann–Whitney test. Asterisks indicate significant differences compared to infected untreated mice. * p < 0.05. p -Values for comparisons between combination therapies and monotherapies at equivalent doses are shown in the graphs.

Article Snippet: Amiodarone hydrochloride was purchased from Sanofi Aventis (Paris, France).

Techniques: Infection, MANN-WHITNEY

Cytokine profiles from BALB/c mice infected with Y T. cruzi strain and treated or untreated. BALB/c mice were infected with Y T. cruzi strain and treated with benznidazole at 100 mg/kg body weight (Bz); ravuconazole at 0.5 mg/kg (Rav 0.5); ravuconazole at 10 mg/kg (Rav 10); amiodarone at 50 mg/kg (Amio) or a combination of ravuconazole 0.5 mg/kg and amiodarone 50 mg/kg (Rav + Amio). Infected untreated controls (INT) received water. NICnon infected controls. Treatments were administered orally from the 5th to the 9th day after infection. IFN-γ (A), TNF-α (B), IL-6 (C), IL-2 (D), IL-4 (E), and IL-10 (F) were quantified in plasma samples collected on the 14th day post-infection. Data are presented as mean ± SD. Asterisks indicate significant differences compared to infected untreated mice. * p < 0.05, ** p < 0.01, *** p < 0.001. p -Values for comparisons between combination therapies and monotherapies at equivalent doses are shown in the graphs.

Journal: ACS Omega

Article Title: Amiodarone and Ravuconazole Combination Potentiates Chemotherapy against Drug-Resistant Trypanosoma cruzi Strains

doi: 10.1021/acsomega.5c00996

Figure Lengend Snippet: Cytokine profiles from BALB/c mice infected with Y T. cruzi strain and treated or untreated. BALB/c mice were infected with Y T. cruzi strain and treated with benznidazole at 100 mg/kg body weight (Bz); ravuconazole at 0.5 mg/kg (Rav 0.5); ravuconazole at 10 mg/kg (Rav 10); amiodarone at 50 mg/kg (Amio) or a combination of ravuconazole 0.5 mg/kg and amiodarone 50 mg/kg (Rav + Amio). Infected untreated controls (INT) received water. NICnon infected controls. Treatments were administered orally from the 5th to the 9th day after infection. IFN-γ (A), TNF-α (B), IL-6 (C), IL-2 (D), IL-4 (E), and IL-10 (F) were quantified in plasma samples collected on the 14th day post-infection. Data are presented as mean ± SD. Asterisks indicate significant differences compared to infected untreated mice. * p < 0.05, ** p < 0.01, *** p < 0.001. p -Values for comparisons between combination therapies and monotherapies at equivalent doses are shown in the graphs.

Article Snippet: Amiodarone hydrochloride was purchased from Sanofi Aventis (Paris, France).

Techniques: Infection, Clinical Proteomics

Effects of T. cruzi infection and etiological treatments on cardiac tissue and splenic index in BALB/c and Swiss mice. Number of nuclei measured in the myocardium of (A) BALB/c and (B) Swiss mice; (C) splenic index from BALB/c and (D) Swiss mice; (E) representative photomicrographs (hematoxylin and eosin staining) of hearts from BALB/c (left panel) and Swiss (right panel) mice infected with Y T. cruzi strain and treated with benznidazole at 100 mg/kg body weight (Bz); ravuconazole at 0.5 mg/kg (Rav 0.5); ravuconazole at 10 mg/kg (Rav 10); amiodarone at 50 mg/kg (Amio) or a combination of ravuconazole 0.5 mg/kg and amiodarone 50 mg/kg (Rav + Amio). Infected untreated controls (INT) received water. NICnon infected controls. Treatments were administered orally from the 5th to the 9th day after infection. Hearts and spleens were collected on the 14th day post-infection. The splenic index was calculated as the spleen weight divided by the body weight × 100 for each animal and normalized to the mean index of uninfected mice. Asterisks indicate significant differences compared to infected, untreated mice. * p < 0.05, ** p < 0.01; **** p < 0.0001. p -Values for comparisons between combination therapies and monotherapies at equivalent doses are shown in the graphs.

Journal: ACS Omega

Article Title: Amiodarone and Ravuconazole Combination Potentiates Chemotherapy against Drug-Resistant Trypanosoma cruzi Strains

doi: 10.1021/acsomega.5c00996

Figure Lengend Snippet: Effects of T. cruzi infection and etiological treatments on cardiac tissue and splenic index in BALB/c and Swiss mice. Number of nuclei measured in the myocardium of (A) BALB/c and (B) Swiss mice; (C) splenic index from BALB/c and (D) Swiss mice; (E) representative photomicrographs (hematoxylin and eosin staining) of hearts from BALB/c (left panel) and Swiss (right panel) mice infected with Y T. cruzi strain and treated with benznidazole at 100 mg/kg body weight (Bz); ravuconazole at 0.5 mg/kg (Rav 0.5); ravuconazole at 10 mg/kg (Rav 10); amiodarone at 50 mg/kg (Amio) or a combination of ravuconazole 0.5 mg/kg and amiodarone 50 mg/kg (Rav + Amio). Infected untreated controls (INT) received water. NICnon infected controls. Treatments were administered orally from the 5th to the 9th day after infection. Hearts and spleens were collected on the 14th day post-infection. The splenic index was calculated as the spleen weight divided by the body weight × 100 for each animal and normalized to the mean index of uninfected mice. Asterisks indicate significant differences compared to infected, untreated mice. * p < 0.05, ** p < 0.01; **** p < 0.0001. p -Values for comparisons between combination therapies and monotherapies at equivalent doses are shown in the graphs.

Article Snippet: Amiodarone hydrochloride was purchased from Sanofi Aventis (Paris, France).

Techniques: Infection, Staining

In vivo impacts of ravuconazole and/or amiodarone in monotherapy and combination against acute T. cruzi infection by the Colombian strain. (A) Parasitemia curve, (B) area under parasitemia curve, (C) weight gain, and (D) splenic index of BALB/c mice infected with Colombian T. cruzi strain and treated with ravuconazole at 0.5 mg/kg body weight (Rav 0.5); amiodarone (Amio) at 50 mg/kg and a combination of ravuconazole 0.5 mg/kg and amiodarone 50 mg/kg (Rav + Amio). INTuntreated infected control. NICnoninfected control. The treatments were administered orally from the 10th to the 14th day after infection. Weight gain as calculated as the difference between final weight (19 days postinfection) and initial weight (10 days postinfection). The splenic index was determined on the 19th day post-infection and calculated as the spleen weight divided by the body weight × 100 for each animal and normalized to the mean index of uninfected mice. (A–C) Mean ± SD, (D) horizontal lines represent the median. # indicates significant difference comparing ravuconazole and combination group ( p < 0.05). Asterisks indicate significant differences compared to infected untreated mice. * p < 0.05, ** p < 0.01. p -Values for comparisons between combined therapy and monotherapies at equivalent doses are shown in the graphs.

Journal: ACS Omega

Article Title: Amiodarone and Ravuconazole Combination Potentiates Chemotherapy against Drug-Resistant Trypanosoma cruzi Strains

doi: 10.1021/acsomega.5c00996

Figure Lengend Snippet: In vivo impacts of ravuconazole and/or amiodarone in monotherapy and combination against acute T. cruzi infection by the Colombian strain. (A) Parasitemia curve, (B) area under parasitemia curve, (C) weight gain, and (D) splenic index of BALB/c mice infected with Colombian T. cruzi strain and treated with ravuconazole at 0.5 mg/kg body weight (Rav 0.5); amiodarone (Amio) at 50 mg/kg and a combination of ravuconazole 0.5 mg/kg and amiodarone 50 mg/kg (Rav + Amio). INTuntreated infected control. NICnoninfected control. The treatments were administered orally from the 10th to the 14th day after infection. Weight gain as calculated as the difference between final weight (19 days postinfection) and initial weight (10 days postinfection). The splenic index was determined on the 19th day post-infection and calculated as the spleen weight divided by the body weight × 100 for each animal and normalized to the mean index of uninfected mice. (A–C) Mean ± SD, (D) horizontal lines represent the median. # indicates significant difference comparing ravuconazole and combination group ( p < 0.05). Asterisks indicate significant differences compared to infected untreated mice. * p < 0.05, ** p < 0.01. p -Values for comparisons between combined therapy and monotherapies at equivalent doses are shown in the graphs.

Article Snippet: Amiodarone hydrochloride was purchased from Sanofi Aventis (Paris, France).

Techniques: In Vivo, Infection, Control

Journal: ACS Omega

Article Title: Amiodarone and Ravuconazole Combination Potentiates Chemotherapy against Drug-Resistant Trypanosoma cruzi Strains

doi: 10.1021/acsomega.5c00996

Figure Lengend Snippet: Ravuconazole and amiodarone in combination impacts on the cytokine profile of BALB/c mice infected with Colombian T. cruzi strain. Pro and anti-inflammatory cytokines detected in sera from BALB/c mice infected with Colombian T. cruzi strain and treated with ravuconazole at 0.5 mg/kg body weight (Rav 0.5); amiodarone at 50 mg/kg (Amio) or a combination of ravuconazole 0.5 mg/kg and amiodarone 50 mg/kg (Rav + Amio). Infected untreated controls (INT) received water. NICnon infected controls. Treatments were administered orally from the 10th to the 14th day after infection. IFN-γ (A), TNF-α (B), IL-6 (C), IL-2 (D), IL-4 (E), and IL-10 (F) were quantified in plasma samples collected on the 19th day post-infection. Data are presented as mean ± SD. Asterisks indicate significant differences compared to infected, untreated mice. * p < 0.05, ** p < 0.01. p -Values for comparisons between combination therapies and monotherapies at equivalent doses are shown in the graphs.

Article Snippet: Amiodarone hydrochloride was purchased from Sanofi Aventis (Paris, France).

Techniques: Infection, Clinical Proteomics

The combination of ravuconazole and amiodarone reduces heart parasite load and myocarditis in mice infected with a benznidazole-resistant strain. (A) Number of nuclei measured in myocardium and (B) representative photomicrographs (hematoxylin and eosin staining) of hearts from BALB/c mice infected with Colombian T. cruzi strain and treated with ravuconazole at 0.5 mg/kg body weight (Rav 0.5); amiodarone at 50 mg/kg (Amio) or a combination of ravuconazole 0.5 mg/kg and amiodarone 50 mg/kg (Rav + Amio). Infected untreated controls (INT) received water. NICnon infected controls. Treatments were administered orally from the 10th to the 14th day after infection. Hearts were collected on the 19th day post-infection. Data are presented as mean ± SD. Asterisks indicate significant differences compared to infected, untreated mice. * p < 0.05. p -Values for comparisons between combination therapies and monotherapies at equivalent doses are shown in the graph. Arrows indicate amastigote nests.

Journal: ACS Omega

Article Title: Amiodarone and Ravuconazole Combination Potentiates Chemotherapy against Drug-Resistant Trypanosoma cruzi Strains

doi: 10.1021/acsomega.5c00996

Figure Lengend Snippet: The combination of ravuconazole and amiodarone reduces heart parasite load and myocarditis in mice infected with a benznidazole-resistant strain. (A) Number of nuclei measured in myocardium and (B) representative photomicrographs (hematoxylin and eosin staining) of hearts from BALB/c mice infected with Colombian T. cruzi strain and treated with ravuconazole at 0.5 mg/kg body weight (Rav 0.5); amiodarone at 50 mg/kg (Amio) or a combination of ravuconazole 0.5 mg/kg and amiodarone 50 mg/kg (Rav + Amio). Infected untreated controls (INT) received water. NICnon infected controls. Treatments were administered orally from the 10th to the 14th day after infection. Hearts were collected on the 19th day post-infection. Data are presented as mean ± SD. Asterisks indicate significant differences compared to infected, untreated mice. * p < 0.05. p -Values for comparisons between combination therapies and monotherapies at equivalent doses are shown in the graph. Arrows indicate amastigote nests.

Article Snippet: Amiodarone hydrochloride was purchased from Sanofi Aventis (Paris, France).

Techniques: Infection, Staining

Flowcharts and experimental designs of the studies. (A) Flowchart of the human study. Exclusions were applied for not meeting all inclusion criteria for the given group. (B) Flowchart of marker gene identification. Continuous lines mark subjects, sequenced lines mark genes. (C) Experimental design of the animal studies. Male THAI mice were treated with amiodarone hydrochloride in the diet (1.35 mg/g chow) for 8 weeks and received T4 intraperitoneally on the last 2 days (166.7 ng/bwg/day T4 in the lungs and BAT study, 250 ng/bwg/day in the heart study). Abbreviations: N, population of investigated subjects; n, subpopulation of subjects; NGS, next-generation sequencing; qPCR, quantitative polymerase chain reaction; T4, thyroxine; THAI, thyroid hormone action indicator mouse.

Journal: The Journal of Clinical Endocrinology and Metabolism

Article Title: Novel Biomarkers Reveal Mismatch Between Tissue and Serum Thyroid Hormone Status in Amiodarone-Induced Hyperthyroidism

doi: 10.1210/clinem/dgae514

Figure Lengend Snippet: Flowcharts and experimental designs of the studies. (A) Flowchart of the human study. Exclusions were applied for not meeting all inclusion criteria for the given group. (B) Flowchart of marker gene identification. Continuous lines mark subjects, sequenced lines mark genes. (C) Experimental design of the animal studies. Male THAI mice were treated with amiodarone hydrochloride in the diet (1.35 mg/g chow) for 8 weeks and received T4 intraperitoneally on the last 2 days (166.7 ng/bwg/day T4 in the lungs and BAT study, 250 ng/bwg/day in the heart study). Abbreviations: N, population of investigated subjects; n, subpopulation of subjects; NGS, next-generation sequencing; qPCR, quantitative polymerase chain reaction; T4, thyroxine; THAI, thyroid hormone action indicator mouse.

Article Snippet: Mice in treated cages received a chow diet containing amiodarone hydrochloride at a concentration of 1.35 g/kg (custom order from SSniff Specialdiäten GmbH; amiodarone hydrochloride obtained from Merck) for 8 weeks , while control animals received normal chow diet.

Techniques: Marker, Next-Generation Sequencing, Real-time Polymerase Chain Reaction

Serum fT4 levels and local thyroid hormone action in lungs, brown adipose tissue, and heart of THAI mice after amiodarone and T4 treatment. Male THAI mice were treated with amiodarone hydrochloride in the diet (1.35 mg/g chow) for 8 weeks and received 166.7 ng/bwg/day (A-C) or 250 ng/bwg/day (D, E) T4 intraperitoneally on the last 2 days. Tissue thyroid hormone action is measured by Luciferase mRNA. One unit increase in –ddCt means a 2-fold increase in gene expression. The figure shows estimates of means ± 95% CI from 2-way crossed analysis of variance model. (A) serum fT4 levels (T4: 166.7 ng/bwg/day). (B) Tissue thyroid hormone action in the lungs. (C) Tissue thyroid hormone action in the BAT. (D) Serum fT4 levels (T4: 250 ng/bwg/day). (E) Tissue thyroid hormone action in the heart. n = 12-13/group (A-C) or 9-10/group (D, E). Abbreviations: T4, thyroxine; BAT, brown adipose tissue; mRNA, messenger RNA; * P < .05; ** P < .01; *** P < .001.

Journal: The Journal of Clinical Endocrinology and Metabolism

Article Title: Novel Biomarkers Reveal Mismatch Between Tissue and Serum Thyroid Hormone Status in Amiodarone-Induced Hyperthyroidism

doi: 10.1210/clinem/dgae514

Figure Lengend Snippet: Serum fT4 levels and local thyroid hormone action in lungs, brown adipose tissue, and heart of THAI mice after amiodarone and T4 treatment. Male THAI mice were treated with amiodarone hydrochloride in the diet (1.35 mg/g chow) for 8 weeks and received 166.7 ng/bwg/day (A-C) or 250 ng/bwg/day (D, E) T4 intraperitoneally on the last 2 days. Tissue thyroid hormone action is measured by Luciferase mRNA. One unit increase in –ddCt means a 2-fold increase in gene expression. The figure shows estimates of means ± 95% CI from 2-way crossed analysis of variance model. (A) serum fT4 levels (T4: 166.7 ng/bwg/day). (B) Tissue thyroid hormone action in the lungs. (C) Tissue thyroid hormone action in the BAT. (D) Serum fT4 levels (T4: 250 ng/bwg/day). (E) Tissue thyroid hormone action in the heart. n = 12-13/group (A-C) or 9-10/group (D, E). Abbreviations: T4, thyroxine; BAT, brown adipose tissue; mRNA, messenger RNA; * P < .05; ** P < .01; *** P < .001.

Techniques: Luciferase, Expressing

Journal: The Journal of Clinical Endocrinology and Metabolism

Article Title: Novel Biomarkers Reveal Mismatch Between Tissue and Serum Thyroid Hormone Status in Amiodarone-Induced Hyperthyroidism

doi: 10.1210/clinem/dgae514

Techniques: Marker, Next-Generation Sequencing, Real-time Polymerase Chain Reaction

Journal: The Journal of Clinical Endocrinology and Metabolism

Article Title: Novel Biomarkers Reveal Mismatch Between Tissue and Serum Thyroid Hormone Status in Amiodarone-Induced Hyperthyroidism

doi: 10.1210/clinem/dgae514

Techniques: Luciferase, Gene Expression

Journal: Biochemical pharmacology

Article Title: Preclinical evaluation of new drug-drug interactions of lomitapide: A proposal for novel mechanism of interaction associated with lipid metabolic changes.

doi: 10.1016/j.bcp.2025.116778

Figure Lengend Snippet: Fig. 1. Decreased serum concentrations of lipids and VLDL/LDL-philic drugs were observed in lomitapide-treated mice. (A) Diagram showing the repeated co- administration study in mice. The study schedule consisted of a 7-day single administration period and a 4-day co-administration period. (B) Cholesterol, (C) tri glyceride, (D) amiodarone, (E) tetracycline, (F) doxycycline, and (G) labetalol concentrations in the serum and VLDL/LDL fractions were measured at the end of the repeated co-administration study. n = 6 mice per group. Data are presented as individual values with mean ± SEM. *p < 0.05, **p < 0.01, significantly different from the lomitapide-untreated group; N.S., not significant from the lomitapide-untreated group; unpaired Student’s t test.

Article Snippet: Amiodarone hydrochloride was purchased from LKT Laboratories (St. Paul, MN, USA).

Techniques:

Journal: Biochemical pharmacology

Article Title: Preclinical evaluation of new drug-drug interactions of lomitapide: A proposal for novel mechanism of interaction associated with lipid metabolic changes.

doi: 10.1016/j.bcp.2025.116778

Figure Lengend Snippet: Fig. 2. Accumulation of lipids and VLDL/LDL-philic drugs was observed in enterocytes of lomitapide-treated mice. The amount of (A) cholesterol (n = 6 mice per group), (B) triglycerides (n = 6 mice per group), (C) amiodarone (n = 6 mice per group), (D) tetracycline (n = 5 mice per group; one point was excluded as an outlier), and (E) doxycycline (n = 6 mice per group) in enter ocytes was measured at the end of the repeated co-administration study. Data are presented as individual values with mean ± SEM. *p < 0.05, **p < 0.01, significantly different from the lomitapide-untreated group; N.S., not significant from the lomitapide-untreated group; unpaired Student’s t test.

Article Snippet: Amiodarone hydrochloride was purchased from LKT Laboratories (St. Paul, MN, USA).

Techniques:

Journal: Biochemical pharmacology

Article Title: Preclinical evaluation of new drug-drug interactions of lomitapide: A proposal for novel mechanism of interaction associated with lipid metabolic changes.

doi: 10.1016/j.bcp.2025.116778

Figure Lengend Snippet: Fig. 3. Accumulation of lipids, but not of VLDL/LDL-philic drugs, was observed in the liver of lomitapide-treated mice. The amount of (A) cholesterol, (B) tri glycerides, (C) amiodarone, (D) tetracycline, and (E) doxycycline in the liver was measured at the end of the repeated co-administration study. n = 6 mice per group. Data are presented as individual values with mean ± SEM. *p < 0.05, **p < 0.01, significantly different from the lomitapide-untreated group; N.S., not significant from the lomitapide-untreated group; unpaired Student’s t test.

Article Snippet: Amiodarone hydrochloride was purchased from LKT Laboratories (St. Paul, MN, USA).

Techniques:

Journal: Biochemical pharmacology

Article Title: Preclinical evaluation of new drug-drug interactions of lomitapide: A proposal for novel mechanism of interaction associated with lipid metabolic changes.

doi: 10.1016/j.bcp.2025.116778

Figure Lengend Snippet: Fig. 4. Inhibition of amiodarone absorption was observed in lomitapide-pretreated mice. (A) Diagram showing the acute absorption study in mice. The study schedule consisted of a 7-day preadministration period followed by the oral administration of amiodarone with olive oil. (B) Cholesterol and (C) triglyceride concentrations in the serum and VLDL/LDL fractions were measured at the end of the 7-day preadministration period. (D) Triglyceride and (E) amiodarone con centrations in the serum and (F) amiodarone concentrations in VLDL/LDL fractions were measured before and 1 and 2 h after the oral administration of amiodarone with olive oil. (G) Amiodarone levels in enterocytes 2 h after oral administration. Black line: lomitapide-untreated group; blue line: lomitapide-pretreated group. n = 6 mice per group. Data are presented as individual values with mean ± SEM. *p < 0.05, **p < 0.01, significantly different from the lomitapide-untreated group; N.S., not significant from the lomitapide-untreated group; unpaired Student’s t test.

Article Snippet: Amiodarone hydrochloride was purchased from LKT Laboratories (St. Paul, MN, USA).

Techniques: Inhibition

Comparison of TCM Symptom Score and AF Burden Changes Following 8-Week Treatment and 6-Month Recurrence Rate Between the Two Groups

Journal: Journal of Inflammation Research

Article Title: Efficacy of Self-Formulated Ergan Tang on Paroxysmal Atrial Fibrillation in Elderly Patients with Qi-Yin Deficiency: Impact on Inflammatory Marker Levels

doi: 10.2147/JIR.S478734

Figure Lengend Snippet: Comparison of TCM Symptom Score and AF Burden Changes Following 8-Week Treatment and 6-Month Recurrence Rate Between the Two Groups

Article Snippet: In the amiodarone group patients received amiodarone hydrochloride tablets (Sanofi, China, Batch No. BHG0175).

Techniques: Comparison

Baseline Clinical Data and Demographic Characteristics of the Two Groups

Journal: Journal of Inflammation Research

Article Title: Efficacy of Self-Formulated Ergan Tang on Paroxysmal Atrial Fibrillation in Elderly Patients with Qi-Yin Deficiency: Impact on Inflammatory Marker Levels

doi: 10.2147/JIR.S478734

Figure Lengend Snippet: Baseline Clinical Data and Demographic Characteristics of the Two Groups

Article Snippet: In the amiodarone group patients received amiodarone hydrochloride tablets (Sanofi, China, Batch No. BHG0175).

Techniques:

Review

Structured Review

Images

1) Product Images from "Preclinical evaluation of new drug-drug interactions of lomitapide: A proposal for novel mechanism of interaction associated with lipid metabolic changes."

Similar Products

Image Search Results